The current landscape of prostate-specific membrane antigen (psma) imaging biomarkers for aggressive prostate cancer
H Al Saffar, DC Chen, C Delgado, J Ingvar, MS Hofman… - Cancers, 2024 - mdpi.com
Simple Summary The review explores the critical role of prostate-specific membrane antigen
(PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT …
(PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT …
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy
There is increasing demand worldwide to develop diagnostic and therapeutic (theranostic)
markers for prostate cancer. One target of interest is prostate-specific membrane antigen …
markers for prostate cancer. One target of interest is prostate-specific membrane antigen …
Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2—A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11
Simple Summary Prostate cancer is the most prevalent cancer among men. Patients
diagnosed with metastatic, castration-resistant prostate cancer (mCRPC) face a highly …
diagnosed with metastatic, castration-resistant prostate cancer (mCRPC) face a highly …
Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model
Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA)-targeted
radiopharmaceutical therapy is a clinically approved treatment for patients with metastatic …
radiopharmaceutical therapy is a clinically approved treatment for patients with metastatic …
[HTML][HTML] Combination Strategies and Targeted Radionuclide Therapies
K Jewell, L Kostos, B Emmerson, MS Hofman - Seminars in Nuclear …, 2024 - Elsevier
Combination models utilising treatments from two or more therapeutic classes are well
established in cancer care. In the new era of theranostic (theragnostic) medicine there is an …
established in cancer care. In the new era of theranostic (theragnostic) medicine there is an …
Role of Lutetium Radioligand Therapy in Prostate Cancer
I Książek, A Ligęza, F Drzymała, A Borek, M Miszczyk… - Cancers, 2024 - mdpi.com
Simple Summary Lutetium-177-PSMA—a radiopharmaceutical composed of a radionuclide
lutetium-177 and a PSMA-binding ligand—is a theranostic medicine for prostate cancer. In …
lutetium-177 and a PSMA-binding ligand—is a theranostic medicine for prostate cancer. In …
Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET Examinations
Simple Summary Radioligand therapies targeting prostate-specific membrane antigen
(PSMA) receptors are currently being investigated in several ongoing trials for their …
(PSMA) receptors are currently being investigated in several ongoing trials for their …
[HTML][HTML] Neoadjuvant chemohormonal therapy before radical prostatectomy in high-risk prostate cancer: a mini-review
J Fan, Z Jiang, G Wang, D He, K Wu - American Journal of Clinical …, 2024 - ncbi.nlm.nih.gov
High-risk localized prostate cancer (PCa) has the potential of recurrence and progression to
a lethal phenotype, and neoadjuvant therapy followed by radical prostatectomy (RP) may be …
a lethal phenotype, and neoadjuvant therapy followed by radical prostatectomy (RP) may be …
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
U Krafft, BA Hadaschik, K Lückerath… - European …, 2023 - pubmed.ncbi.nlm.nih.gov
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer? A New Chapter in
Neoadjuvant Therapy for High-risk Prostate Cancer? Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4 …
Neoadjuvant Therapy for High-risk Prostate Cancer? Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4 …
Treatment and Staging Intensification Strategies Associated with Radical Prostatectomy for High-Risk Prostate Cancer: Efficacy Evaluation and Exploration of Novel …
G Reitano, T Ceccato, S Botti, M Bruniera, S Carrozza… - Cancers, 2024 - mdpi.com
The management of high-risk prostate cancer (PCa) presents a significant clinical challenge,
often necessitating treatment intensification due to the potential presence of …
often necessitating treatment intensification due to the potential presence of …